Specialty Pharmacy Continuum: Not All Pay-for-Performance Programs Pay Off

A pay-for-performance (P4P) program by a national insurance company improved evidence-based prescribing of cancer drug regimens but did not yield cost savings, according to results of a study by researchers from the University of Pennsylvania. “In general, pay-for-performance programs have had a mixed history in health care policy,” said Justin E. Bekelman, MD, the director of the Penn Center for Cancer Care Innovation, in Philadelphia, and lead investigator on the study. “So, our motivation was to understand [how the model performed] in the largest program of its kind in the U.S. and most likely the world.” Read more at Specialty Pharmacy Continuum.